BioCentury

Publication

0 followers

Provides in-depth analysis and business intelligence for biopharma executives and investors, with independent reporting to inform strategic decisions in biotech.

Pharma CEOs Should Demand Prasad’s Departure

BioCentury’s editorial warns that the current director of the FDA’s Center for Biologics Evaluation and Research (CBER) is jeopardizing patient safety and destabilizing the pharmaceutical industry. The author cites the director’s handling of Moderna’s flu vaccine as a recent example of overreach that could set a precedent for future biologics approvals. By imposing unpredictable regulatory demands, the CBER leadership is inflating development costs and delaying market entry for critical therapies. The piece urges pharma CEOs to collectively demand the director’s removal to restore regulatory stability.

Technology Pulse

BioCentury

Recent Posts

Pharma CEOs Should Demand Prasad’s Departure

A Thousand Physicians Call on FDA to Reverse CRL for Myopia Drug

FDA’s Accelerated Approval Messaging Collides with CRL Reality

Start-Up Funding, the Perils of Compounding, and Neuropsych Insights — a BioCentury Podcast

Galux: Scaling AI-Designed Biologics

The Next Wave of Biotech Growth — a Perspective

Galux Secures $29M Series B Funding Led by Yuanta

McKinsey Vet Franck Le Deu Joins Nisa Leung’s New Fund; Plus C-Suite Shuffle at Bicycle

Series A Companies: Biotech’s Class of 2025

Sanofi Misses in Fabry: Is It Time to Move on From GCS Inhibition in the Indication?

Latent Labs: AI-Designed, Ready-to-Develop Biologics

Serendipity Drives Discovery in Psychiatry, Engineering Gets It Across the Line, Says Steve Paul

Angitia’s Latest Megaround to Fuel Mid-Stage Milestones: Venture Report

Dialing Out the Hallucinogenic Effect of Psychedelics — BioCentury’s Science Spotlight

Asking Amgen to Withdraw Tavneos, FDA Revisits Years-Old Data Issue

Even Endpoint Hits Don’t Spare Shares in Three Weight-Loss Updates

Rep. Auchincloss Challenges Legality of Commissioner’s National Priority Voucher Program

Spending Law a Rebuke to Proposed White House Biomedical Cuts

Biotech’s 2026 Catalysts. Plus: China’s New Orphan Rules — a BioCentury Podcast

EMA’s CHMP Backs Six New Products in January

At Least Nine PDUFAs on FDA February Docket

2026 Cardiovascular Catalysts: Lp(a) on the Horizon

2026 Catalysts: Breakthrough Progress in Renal Disease

Survey Results: What Sponsors Say Is Slowing Cancer Trials — and What’s Helping

AZ Signals All-In on Obesity via CSPC Deal for $1.2B up Front

AstraZeneca Signs $1.2B Upfront Deal with CSPC for Obesity Assets

2026 Catalysts: The Rise of RNAi

Changes in Cardiff’s C-Suite Amid Late-Stage Push for Cancer Candidate

China’s Orphan Drug Exclusivity Could Bolster Market, Incentivize Development

Broadening T Cell Control in Atopic Dermatitis

2026 Catalysts: Psychiatry, Epilepsy and Neurodegeneration

Miles Gerson, Sofia Guerra Among VCs Landing New Roles

Speeding China’s Innovation. Plus: 2026’s Neuro Catalysts — a BioCentury Podcast

New Rules Add Rigor While Fueling China’s Gene and Cell Therapy Engine

Brisk Demand for Follow-Ons Could Augur IPO Appetite: Public Equity Report

With De-Risking the Mantra, Novartis Expands Presence in RNAi: Narasimhan in Conversation

Ovarian Cancer Data Give Corcept’s Shares a Bounce After Year-End CRL Drop

Corxel Draws $287M Round to Drive Global Development of Oral GLP-1

Astellas’ Okamura: The Bottleneck Isn’t Money — It’s Translation

FDA Takes Step Toward Innovation-Supporting Endpoints with MRD Negativity Guidance

Biotech’s Bull Is Back — and Investors Think It Can Stick

TAC to the Future. Plus: GSK’s Rapt Deal, Codifying MFN — a BioCentury Podcast

4Q25 Wrap: Megacaps Surge in 4Q as All Boats Rise for the Year

Parabilis’ Path From POC to New Indications and Challenging Targets

Parabilis Secures $305M Crossover Round to Advance Helicon Platform

Congress Advances PRV Reauthorization, NIH Funding, Multi-Cancer Detection Coverage

JPM Movers: ImmunityBio Rises to the Top

Korea’s Ildong Promotes Chae Joon Lee to Co-CEO

More Cash Flows Into Biotechs During Conference Week: Finance Report

JPM Momentum and Asia’s Hotbeds of Innovation — a BioCentury Podcast

2026 U.S. Drug Pricing Outlook: ‘MFN’ Is the Future

PROTAC Bottleneck Breakthroughs

Eli Lilly to Acquire Ventyx for $1.2B

Amgen Acquires AML Candidate From UK Biotech Dark Blue

Technology Pulse

BioCentury

Recent Posts

Pharma CEOs Should Demand Prasad’s Departure

A Thousand Physicians Call on FDA to Reverse CRL for Myopia Drug

FDA’s Accelerated Approval Messaging Collides with CRL Reality

Start-Up Funding, the Perils of Compounding, and Neuropsych Insights — a BioCentury Podcast

Galux: Scaling AI-Designed Biologics

The Next Wave of Biotech Growth — a Perspective

Galux Secures $29M Series B Funding Led by Yuanta

McKinsey Vet Franck Le Deu Joins Nisa Leung’s New Fund; Plus C-Suite Shuffle at Bicycle

Series A Companies: Biotech’s Class of 2025

Sanofi Misses in Fabry: Is It Time to Move on From GCS Inhibition in the Indication?

Latent Labs: AI-Designed, Ready-to-Develop Biologics

Serendipity Drives Discovery in Psychiatry, Engineering Gets It Across the Line, Says Steve Paul

Angitia’s Latest Megaround to Fuel Mid-Stage Milestones: Venture Report

Dialing Out the Hallucinogenic Effect of Psychedelics — BioCentury’s Science Spotlight

Asking Amgen to Withdraw Tavneos, FDA Revisits Years-Old Data Issue

Even Endpoint Hits Don’t Spare Shares in Three Weight-Loss Updates

Rep. Auchincloss Challenges Legality of Commissioner’s National Priority Voucher Program

Spending Law a Rebuke to Proposed White House Biomedical Cuts

Biotech’s 2026 Catalysts. Plus: China’s New Orphan Rules — a BioCentury Podcast

EMA’s CHMP Backs Six New Products in January